ClinicalTrials.gg

Program

emfizatamab

Its studies are mostly in Lymphoma, Non-Hodgkin · Lupus Erythematosus, Systemic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Extranodal NK-T-Cell · Arthritis, Rheumatoid, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 2, since Dec 15, 20217 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical77 open or runningphase 2since Dec 15, 2021Oct 8, 2020Dec 2026phase 2 · NCT05623982

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 8, 2020First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT04606433 · 47 enrolled · China
  2. Dec 15, 2021Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05192486 · 12 enrolled · China
  3. Jul 31, 2022Phase 2 study in Primary Central Nervous System LymphomaNCT05485753 · 7 enrolled · China
  4. Aug 25, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05623982 · 40 planned · China
  5. Nov 8, 2022Phase 2 study in Lymphoma, Extranodal NK-T-CellNCT05627856 · 4 enrolled · China
  6. Feb 26, 20252 phase 1 studiesNCT06857227, NCT06857214

Ahead

  1. Dec 2026Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT05623982
  2. Dec 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT06857227
  3. Dec 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06857214

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06857227Arthritis, Rheumatoid · China1RecruitingDec 202754
NCT06857214Lupus Erythematosus, Systemic · China1RecruitingDec 202784
NCT05627856Lymphoma, Extranodal NK-T-Cell · China2Active, not recruitingDec 20254
NCT05623982Lymphoma, Non-Hodgkin · China2RecruitingDec 202640
NCT05485753Primary Central Nervous System Lymphoma · China2Active, not recruitingDec 20257
NCT05192486Lymphoma, Large B-Cell, Diffuse · China2Active, not recruitingDec 202512
NCT04606433Lymphoma, Non-Hodgkin · China1Active, not recruitingDec 202547

How it is read

Names in the registry

  • “GNC-038”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.